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Autoimmune lymphoproliferative syndrome (ALPS) is
classified among primary immune deficiencies. This pro-
totypic disorder of impaired apoptosis in humans is
characterized mainly by autoimmune features and lym-
phoproliferation. ALPS type 0, caused by homozygous
null mutations of the CD95 gene (Fas) leading to a
severe ALPS phenotype, is a very rare subgroup with
only 3 published cases. Here, we describe two North
African male infants (a Tunisian and a Libyan) with
ALPS 0 syndrome. They are born to consanguineous
parents and were both investigated at age 10 months for
lymphadenopathy, splenomegaly and auto-immune
hemolytic anemia. The two patients showed increased
levels of serum immunoglobulins. Immunophenotyping
showed a high percentage (15% and 11% respectively) of
CD4-CD8-TCRab+ and a complete absence of Fas
expression. As previously described, we found elevated
levels of IL-10 protein (1934pg/ml and 771pg/ml respec-
tively) and sFasLigand (1.7ng/ml and >5ng/ml respec-
tively) in their plasma. RT-PCR analysis demonstrated
the skipping of exon 6, coding for the Fas transmem-
brane domain, for both patients. Sequencing analysis of
the Fas gene showed that one patient has a homozygous
substitution 16 nucleotides upstream of the 3’ acceptor
splice site of intron 5 (c.506-16A>G). This mutation
may result in profound defects of gene expression at the
level of pre-mRNA splicing as it breaks a potential
branch point sequence. The other patient has a homozy-
gous substitution within exon 6 (c.514C>T) which alters
a potential exonic regulatory splicing site. These predic-
tions have been obtained using human splicing finder
software. The parents DNA was available for one patient
and both were healthy heterozygous. Furthermore, these
mutations were not found in 30 healthy individuals
excluding a potential polymorphism. The two identified,
previously non described mutations result in absent sur-
face expression of the Fas receptor, precluding binding
of FasL and leading to severe clinical symptoms. They
expand on the few previously reported ALPS 0 cases
and provide further insights into Fas gene molecular
defects.
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